Based on the BEXIMCO PHARMA.GDR REGS 1 stock forecast from 0 analysts, the average analyst target price for BEXIMCO PHARMA.GDR REGS 1 is not available over the next 12 months. BEXIMCO PHARMA.GDR REGS 1’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BEXIMCO PHARMA.GDR REGS 1 is Bullish , which is based on 6 positive signals and 2 negative signals. At the last closing, BEXIMCO PHARMA.GDR REGS 1’s stock price was EUR 0.436. BEXIMCO PHARMA.GDR REGS 1’s stock price has changed by +0.00% over the past week, -3.11% over the past month and +3.81% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for R2WA:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
